Ikena Oncology (IKNA) Revenue & Revenue Breakdown
Ikena Oncology Revenue Highlights
Latest Revenue (Y)
$9.16M
Ikena Oncology Revenue by Period
Ikena Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $9.16M | -41.35% |
| 2022-12-31 | $15.62M | -49.59% |
| 2021-12-31 | $30.98M | 237.01% |
| 2020-12-31 | $9.19M | -33.15% |
| 2019-12-31 | $13.75M | - |
Ikena Oncology generated $9.16M in revenue during NA 2023, up -41.35% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Ikena Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $659.00K | -44.39% |
| 2023-09-30 | $1.19M | -40.87% |
| 2023-06-30 | $2.00M | -62.28% |
| 2023-03-31 | $5.31M | -2.51% |
| 2022-12-31 | $5.45M | -14.87% |
| 2022-09-30 | $6.40M | 1575.92% |
| 2022-06-30 | $382.00K | -88.71% |
| 2022-03-31 | $3.38M | -83.26% |
| 2021-12-31 | $20.22M | 439.70% |
| 2021-09-30 | $3.75M | 5.55% |
| 2021-06-30 | $3.55M | 2.16% |
| 2021-03-31 | $3.47M | 5244.62% |
| 2020-12-31 | $65.00K | -97.70% |
| 2020-09-30 | $2.83M | -7.94% |
| 2020-06-30 | $3.07M | -4.77% |
| 2020-03-31 | $3.23M | 15.09% |
| 2019-12-31 | $2.80M | - |
Ikena Oncology generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Ikena Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| RZLT | Rezolute | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| DBTX | Decibel Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CELC | Celcuity | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
IKNA Revenue FAQ
What is Ikena Oncology’s yearly revenue?
Ikena Oncology's yearly revenue for 2023 was $9.16M, representing a decrease of -41.35% compared to 2022. The company's yearly revenue for 2022 was $15.62M, representing a decrease of -49.59% compared to 2021. IKNA's yearly revenue for 2021 was $30.98M, representing an increase of 237.01% compared to 2020.
What is Ikena Oncology’s quarterly revenue?
Ikena Oncology's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $659K, a -44.39% decrease from the previous quarter (Q3 2023), and a -87.91% decrease year-over-year (Q4 2022). IKNA's quarterly revenue for Q3 2023 was $1.18M, a -40.87% decrease from the previous quarter (Q2 2023), and a -81.49% decrease year-over-year (Q3 2022).
What is Ikena Oncology’s revenue growth rate?
Ikena Oncology's revenue growth rate for the last 3 years (2021-2023) was -70.44%, and for the last 5 years (2019-2023) was -33.40%.